Sai Parenterals Subsidiary Noumed Secures Landmark AUD 202 Million Exclusive OTC Supply Deal in Australia

Sai Parenterals Limited is making waves in the global pharmaceutical market, with its Australian subsidiary, Noumed Pharmaceuticals Pty Limited, bagging a truly landmark deal. This strategic move is set to significantly bolster the company’s international footprint and revenue streams, signaling robust growth ahead.The Indian-origin pharma major, through Noumed, has inked an exclusive Over-the-Counter (OTC) medicines supply agreement with Australia’s leading pharmacy network. Valued at an impressive Australian Dollars (AUD) 202 million – equivalent to a substantial INR 1300 crores – this long-term contract is a testament to Sai Parenterals’ growing capabilities and market trust. Commencing July 1st, 2026, the agreement spans 7.5 years, with a built-in option for a further 3-year extension, ensuring sustained revenue visibility and market presence.

This isn’t just a big number; it’s a strategic coup.

Key Highlights of the Deal:

• Contract Value: AUD 202 Million (INR 1300 Crores)
• Duration: 7.5 years, with an option for a 3-year extension
• Nature: Exclusive OTC Medicine Supply Agreement
• Market: Australia’s Leading Pharmacy Network

The exclusivity clause is particularly noteworthy, securing Noumed’s position as a primary supplier within a significant distribution channel. For Sai Parenterals, this translates into diversified geographical revenue, enhanced brand recognition in a developed market, and a stable, predictable income stream for nearly a decade. It underscores the company’s commitment to global expansion and its ability to secure high-value international partnerships.

Investors will likely view this development positively, as it de-risks future revenue projections and highlights the operational strength of its overseas ventures. Sai Parenterals’ latest achievement through Noumed Pharmaceuticals positions it as a formidable player in the international OTC market, poised for sustained growth and profitability in the years to come.